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Abstract
Francisella tularensis is a facultative intracellular bacterium and the causative agent of tularemia. Development of novel
vaccines and therapeutics for tularemia has been hampered by the lack of understanding of which immune components are
required to survive infection. Defining these requirements for protection against virulent F. tularensis, such as strain SchuS4,
has been difficult since experimentally infected animals typically die within 5 days after exposure to as few as 10 bacteria.
Such a short mean time to death typically precludes development, and therefore assessment, of immune responses directed
against virulent F. tularensis. To enable identification of the components of the immune system that are required for survival
of virulent F. tularensis, we developed a convalescent model of tularemia in C57Bl/6 mice using low dose antibiotic therapy
in which the host immune response is ultimately responsible for clearance of the bacterium. Using this model we
demonstrate abTCR
+ cells, cdTCR
+ cells, and B cells are necessary to survive primary SchuS4 infection. Analysis of mice
deficient in specific soluble mediators shows that IL-12p40 and IL-12p35 are essential for survival of SchuS4 infection. We
also show that IFN-c is required for survival of SchuS4 infection since mice lacking IFN-cR succumb to disease during the
course of antibiotic therapy. Finally, we found that both CD4
+ and CD8
+ cells are the primary producers of IFN-cand that
cdTCR
+ cells and NK cells make a minimal contribution toward production of this cytokine throughout infection. Together
these data provide a novel model that identifies key cells and cytokines required for survival or exacerbation of infection
with virulent F. tularensis and provides evidence that this model will be a useful tool for better understanding the dynamics
of tularemia infection.
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Introduction
Francisella tularensis is a Gram negative, facultative intracellular
pathogen. Currently, there are five major subspecies of F. tularensis.
Little is known about subspecies philomargia and medasiatica with the
exception that they are not considered pathogenic to the
immunocompetent host [1,2]. Subspecies novicida is also relatively
non-pathogenic to humans [2]. However, it has been employed by
many laboratories as a model intracellular pathogen that resides in
the cytosol of host cells. Subspecies holarctica can cause disease in
humans, but is rarely fatal. However, this subspecies readily infects
and causes lethal disease in mice [3,4]. Perhaps more importantly,
further attenuation of subspecies holarctica resulted in generation of
the Live Vaccine Strain (LVS) [5]. Although LVS is no longer
routinely used in the United States as a vaccine against tularemia,
this strain exhibits route and dose dependent virulence in mice.
Furthermore, mice that survive sublethal challenge with LVS are
immune to secondary lethal challenge [6]. Together, and similar
to F. novicida, these phenomena make LVS infection in mice an
interesting model for requirements of immunity against intracel-
lular pathogens.
Subspecies tularensis was the first isolated organism of the F.
tularensis species and, in stark contrast to other subspecies, is highly
pathogenic for humans [7,8]. Exposure to as few as 15 bacteria
can result in severe, potentially lethal, disease. Mice are also highly
susceptible to infection with subspecies tularensis, and serve as a
useful rodent model to study this pathogen. However, as observed
in humans, evidence of early immune responses directed against
strains of F. tularensis ssp. tularensis (such as SchuS4) is not apparent
[9,10]. Further, when paired with a short mean time to death, e.g.
5 days, dissection of the requirements for immunity against
subspecies tularensis has been difficult.
Despite variability in virulence, all tested subspecies of F.
tularensis appear to target phagocytic cells for replication, readily
escaping into the cytosol following receptor mediated uptake
[11,12]. Thus, one solution to the challenges posed by infection of
mice with virulent F. tularensis was to use either attenuated novicida
or holarctica, specifically LVS, as surrogates for infection with
highly virulent strains. However, over the last several years it has
become apparent that the interactions of attenuated and virulent
subspecies of F. tularensis with host cells are not the same. For
example, evasion of stimulation of rapid pro-inflammatory
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subspecies tularensis [9,13–16]. In contrast, both subspecies novicida
and strain LVS induce inflammatory responses in human cells
[17–19]. We recently reported that virulent F. tularensis induces
IFN-b as a mechanism to suppress IL-12, whereas LVS infection
failed to exhibit this activity [20]. Virulent F. tularensis also
possesses the ability to utilize the host plasminogen system for
degradation of opsonizing antibodies. LVS lacks the ability to
engage the host plasminogen system for this purpose [21]. In vivo,
novicida induces rapid recruitment of granulocytic cells, whereas
recruitment of these cells following infection with subspecies
tularensis is markedly delayed [15]. Thus, it is unclear if the
mechanisms by which novicida or LVS manipulate the host
immune system will be consistent with those utilized by fully
virulent subspecies tularensis.
In addition to variability in the pathogenesis of infection with
attenuated versus virulent strains, there are also inconsistent results
obtained from different labs studying the same attenuated strains
of F. tularensis. For example, early analysis of LVS infection in mice
deficient for IL-12p40 and IL-12p35 suggested that neither of
these cytokines were required to survive LVS infection [22].
However, later publications using the same genetically deficient
mice presented data that both IL-12p35 and IL-12p40 were
required for survival in LVS infection [23]. Similarly, it has been
suggested that induction of IL-4 following LVS infection of
macrophages exacerbates disease [24]. In contrast, other labora-
tories have shown that production of IL-4 aids in clearance of LVS
infection and that LVS can inhibit inflammation mediated, in
part, by IL-4 [25,26]. Furthermore, the ability of attenuated
strains to provoke cytokine production and activate the inflamma-
some among infected host cells has also been a point of
controversy [27–30]. Given the contrasting results obtained with
attenuated subspecies, and the difference in pathogenesis between
virulent and attenuated subspecies, it is difficult to apply findings
from infection with attenuated subspecies to those mediated by
fully virulent F. tularensis. Together this emphasizes the importance
for assessment of the requirements of protection against tularemia
using fully virulent strains of F. tularensis.
A small number of studies with virulent F. tularensis have
successfully identified requirements for survival of infection in
vaccinated mice and host components that exacerbate disease in
naive animals [31–35]. However, most experiments designed to
determine host requirements for immunity against virulent F.
tularensis in vivo are hampered by the low dose of bacteria capable
of causing uniformly lethal disease and a very short mean time to
death, i.e. 10–15 bacteria and approximately 5 days, respectively.
Development of a model using virulent F. tularensis that allows for
examination of bacterial-host interactions over longer periods of
time would potentially resolve this problem for studying immunity
to tularemia.
As a bacterium, F. tularensis can be killed by antibiotics.
Therefore, antibiotics could be used to control and/or clear
infection with virulent F. tularensis in experimentally infected
animals. This process may extend the course of primary infection
and allow investigation of the role of specific host cells and soluble
mediators that play a role in tularemia. Previous studies have
shown that treatment with the fluoroquinolone levofloxacin in
Balb/c mice aids in clearance of SchuS4 following intranasal
infection [36]. Furthermore, antibiotic treated Balb/c mice were
resistant to secondary challenge with SchuS4, a feature that was
attributed to the production of antibodies directed against
Francisella. However, the requirement for other immune compo-
nents was not investigated. These studies would be difficult in
Balb/c mice for the practical reason that the majority of mice with
specific genetic deficiencies, which would allow assessment of the
role of specific cells and molecules, are bred on a C57Bl/6
background and not Balb/c.
The goal of the study presented herein was to develop a model
of convalescent tularemia in C57BL/6 in which the host immune
response, rather than antibiotic alone, ultimately controlled
infection. This model would then be used to assess the requirement
for specific cells and soluble mediators for control and/or
resolution of disease mediated by virulent F. tularensis. Additionally,
this model would result in median survival, e.g. 50–60%, of wild
type animals to enable assessment of host components that either
aid in resolution or exacerbation of disease. Herein, we describe
the generation of such a model in C57BL/6 mice and identify key
host cells and cytokines required to survive primary SchuS4
infection.
Results
Survival of F. tularensis SchuS4 infection following
delivery of low dose antibiotic
Antibiotics can be used in humans and mice to effectively treat
tularemia [37–39]. A recent report demonstrated intraperitoneal
injection of 40 mg/kg of the fluoroquinolone levofloxacin (LVF)
delivered daily for 14 days aids in the resolution of virulent F.
tularensis infection in Balb/c mice [36]. However, efficacy of LVF
in C57Bl/6 mice has not been examined. Since the majority of
mice with targeted deletions in genes participating in immune
responses are on a C57Bl/6 background, we first tested a dose of
40 mg/kg of LVF for its ability to enhance survival of intranasal
SchuS4 infection in C57Bl/6 mice. Similar to reports in Balb/c
mice, 100% of C57Bl/6 mice receiving 40 mg/kg of LVF
beginning on day 1, 2 or 3 after infection with SchuS4 survived
(Figure 1A). However, in contrast to data obtained from Balb/c
mice, surviving C57Bl/6 mice are poorly protected against a
second challenge of SchuS4 (Figure 1A). Specifically, 30% of
animals treated with 40 mg/kg LVF beginning on day 1 of
infection survive secondary challenge, whereas only 20% of
animals receiving this dose of LVF on day 2 or 3 of primary
infection survive secondary challenge (Figure 1A).
Survival of approximately 50–60% of animals treated with LVF
would enable in vivo assessment of host components that
contribute to either the resolution or exacerbation of primary
SchuS4 infection. Treatment of mice with 40 mg/kg LVF did not
result in survival rates that fell within this range. Therefore, we
next tested a lower dose of LVF for its ability to aid in resolution of
SchuS4 infection with the goal of reducing survivorship from
100% to approximately 50%. Similar to mice that received
40 mg/kg on day 1 or 2 after infection, all mice receiving 5 mg/kg
LVF beginning on day 1 or 2 after intranasal infection survive
(Figure 1B). However, unlike the minimal survival of secondary
infection observed in mice treated with 40 mg/kg LVF, none of
the mice given 5 mg/kg beginning on day 1 or 2 after infection
survive secondary challenge with SchuS4 (Figure 1B). In contrast,
delay of initiation of LVF therapy to day 3 of primary SchuS4
infection resulted in survival of 60% of the mice (Figure 1B). All
mice that received LVF treatment beginning on day 3 of infection
and survived to 30 days post-infection had circulating antibodies
directed against F. tularensis, indicating all mice had been infected
with SchuS4 (Figure S1). Furthermore, animals treated with
5 mg/kg beginning on day 3 of primary SchuS4 infection also
exhibited the best survival of secondary challenge with approxi-
mately 66% of mice surviving a second intranasal infection with
SchuS4. Thus, delivery of a low dose LVF (i.e. 5 mg/kg)
beginning on day 3 of primary intranasal SchuS4 infection results
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challenge that will allow assessment of host components required
for resolution or exacerbation of both primary and secondary
intranasal SchuS4 infection.
Kinetics of SchuS4 replication following delivery of low
dose LVF
We next determined if survival of SchuS4 infection following
antibiotic therapy correlated with control of bacterial replication
in target organs. Our goal was to establish a persistent infection
that was cleared only after antibiotic therapy was stopped. Mice
were infected with SchuS4 and treated with 5 mg/kg LVF as
described in the Materials and Methods. At the indicated time
points, lungs and spleens were assessed for bacterial loads. Within
24 hours of treatment, LVF restricted splenic and pulmonary
replication of SchuS4 (Figure 2). Throughout the course of LVF
therapy, bacterial numbers in the spleen continued to decrease to
nearly undetectable numbers 14 days after infection (11 days of
LVF treatment) (Figure 2). However, within 5 days of stopping
LVF treatment, numbers of SchuS4 recovered from the spleen
were similar to those observed in LVF treated animals 4 days after
infection (1 day after LVF treatment) (Figure 2). In contrast to the
reduction of SchuS4 in the spleen, LVF treatment had a smaller
impact on the number of bacteria present in the lung. We
observed approximately 1 log10 reduction of SchuS4 in the lungs
of LVF treated animals during LVF therapy as opposed to nearly 2
log10 reduction in the spleen (Figure 2). Furthermore, after LVF
treatment ended, we observed a modest increase in the numbers of
SchuS4 in the lung (Figure 2). Surprisingly, despite the increase in
bacterial numbers in the lung and spleen 21 days after infection,
no bacteria were detected in animals that survived to 30 days after
infection (data not shown). Infection of these survivors was
confirmed by testing sera for antibodies directed against
Francisella. Thirty days after infection, all surviving animals had
measurable titers of circulating anti-Francisella antibodies (Figure
S1). Thus, survival of SchuS4 infection following treatment with
antibiotic correlates with control of bacterial replication during
LVF therapy and eventual clearance of the organisms within 2
weeks after the course of antibiotic therapy is complete.
Furthermore, these data suggest that treatment with low doses of
antibiotic alone is not sufficient for clearance of SchuS4. Rather,
eradication of the bacterium is dependent on appropriate host
immune response directed against this pathogen which is present
when antibiotic is withdrawn.
Pathological Changes following SchuS4 infection and
low dose LVF therapy
We next assessed pathological changes in the lungs and spleens
of SchuS4 infected mice following infection and treatment with
LVF. Consistent with previous observations, by day 4 after
infection, untreated animals have significant pathological changes
in both the lung and spleen (Figure 3 and 4 [40–42]). In the lung,
pulmonary lesions are consistent with necrotizing pneumonia with
effacement of the pulmonary parenchyma and replacement with
cellular and karyorrhectic debris, fibrin, and degenerate neutro-
phils (Figure 3C and D). Similarly, 4 days after SchuS4 infection
untreated animals exhibit serious necrosis in the spleen with
architecture of the spleen diffusely effaced and replaced by
necrotic debris; there is also extensive loss of white pulp (Figure 4C
and D). These changes are consistent with previous observations of
Figure 1. Dose and timing of antibiotic therapy following intranasal infection with virulent F. tularensis ssp tularensis strain SchuS4.
Groups of 5–10 C57Bl/6 mice were intranasally infected with 50 CFU SchuS4 in 25 ml. At the indicated time points after infection mice were injected
intraperitoneally once daily with 40 (A) or 5 mg/kg (B) LVF diluted in 5% dextrose water. All mice were treated for 14 days. Thirty days after primary
challenge all surviving animals (primary survivors) were re-challenged (secondary challenge) intranasally with 50 CFU SchuS4. *=p,0.05 compared
to untreated controls and mice receiving antibiotic from day 3–16. **=p,0.05 compared to untreated controls and mice receiving LVF on day 3.
***=p,0.05 compared untreated mice. Data in each graph is representative of 4 experiments of similar design.
doi:10.1371/journal.pone.0033349.g001
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mice [43].
In contrast to untreated animals, mice that received LVF have
milder pathological changes at 4 days after infection. Specifically,
pulmonary lesions in these animals consisted of multifocal
neutrophilic bronchopneumonia. However, by day 7 after
infection the nature of the lesions has changed. A multifocal
subacute bronchopneumonia characterized by infiltrates of
moderate numbers of macrophages, lymphocytes, and neutrophils
that surround multiple bronchioles and expand the adjacent
alveolar septae is evident in all lungs (Figure 3G and H). This non-
progressing bronchopneumonia is also observed at 10 and 14 days
after infection (Figure 3I–L). Twenty-one days after infection new
changes in pulmonary pathology are observed compared to day 7–
14, with a much larger influx of neutrophils admixed with smaller
numbers of macrophages and lymphocytes (Figure 3 M and N).
Many of the neutrophils are degenerate and there is cellular and
karyorrhectic debris (necrosis) within the alveolar spaces. Howev-
er, by day 30 after infection lesions have resolved and the lung
tissue have returned to normal (Figure 3 O and P). In the spleens
of SchuS4 infected mice treated with LVF, a similar pattern of
slowly resolving pathology followed by recrudescences of lesions to
those observed in the lungs of day 4 infected animals is apparent.
Specifically, 4 days after infection, spleens of LVF treated mice
have multifocal foci of viable and degenerate neutrophils within
the red pulp and within many follicular centers (Figure 4E and F).
There was also a mild depletion of lymphocytes within the white
pulp. Seven days after infection the spleen is expanded by
extramedullary hematopoiesis (EMH) that is composed predom-
inantly of large numbers of blastic erythroid precursor cells and
smaller numbers of nucleated red blood cells (Figure 4G and H).
By day 10 after infection, the nature of the EMH has changed and
Figure 2. Clearance of SchuS4 following antibiotic therapy. Mice were infected intranasally with 50 CFU SchuS4. Three days after infection
mice were treated once daily with 5 mg/kg LVF diluted in 5% dextrose water intraperitoneally for 14 days. At the indicated time points, animals
(n=5/group) were euthanized and lungs and spleens were assessed for bacterial loads. Error bars represent SEM. *=p,0.05 compared to untreated
controls. Data is representative of 2 experiments of similar design.
doi:10.1371/journal.pone.0033349.g002
Figure 3. Pathological changes in the lungs of SchuS4 infected mice following antibiotic therapy. Mice were infected intranasally with
50 CFU SchuS4. Three days after infection mice were treated once daily with 5 mg/kg LVF diluted in 5% dextrose water intraperitoneally for 14 days.
At the indicated time points, lungs from untreated, SchuS4 infected animals (C and D) and SchuS4 infected mice treated with LVF (E–P) were fixed,
sectioned, strained with H&E and assessed for pathological changes. Uninfected mice (A and B) served as normal controls. Representative
photomicrographs for each time point are shown. Plates A, C, E, G, I, K, M, and O are at 26magnification and plates B, D, F, H, J, L, N, P are 406
magnification of the areas indicated by the arrows on the 26plates.
doi:10.1371/journal.pone.0033349.g003
Host Requirements for Survival of Tularemia
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33349is composed primarily of large numbers of nucleated red blood
cells and fewer blastic cells in the red pulp (Figure 4 I and J).
Within 14 days of infection the spleen has nearly returned to
normal with some mild EMH (Figure K and L). However, at day
21 after infection there is a recrudescence of splenitis characterized
by multifocal to coalescing foci of neutrophils and macrophages
that efface the normal architecture (Figure 4M and N). In
addition, there is lymphoid depletion that closely resembles that
seen in the untreated mice at 4 days after infection. In mice that
survive to 30 days after infection and cleared SchuS4 infection
spleens are largely normal with only rare, small, lesions present
(Figure 4O and P). In contrast to surviving mice, animals that
succumb to infection between day 21 and 30 exhibited pathology
in the lung and spleen indistinguishable from that observed in
untreated animals 4 days after infection (Figure 5B–E).
Survival of SchuS4 infection requires T cells and B cells
Previous studies have shown that both T cells and B cells
participate in the control and resolution of infections mediated by
attenuated strains of F. tularensis [34,44–46]. The importance of
these cellular subsets in control of primary infection with less
virulent strains of F. tularensis has been further highlighted by the
inability of severe combined immunodeficiency (SCID) mice
(which do not have T or B cells, but possess NK cells as the
primary effector cell population) to fail in their resolution of
infection with attenuated F. tularensis [33]. Thus, we next
determined if T and B cells played a similarly important role in
survival of primary infection with virulent F. tularensis. Mice lacking
abTCR expressing T cells, e.g. CD4
+ and CD8
+ T cells, survive F.
tularensis infection during administration of antibiotic. However, all
abTCR deficient animals succumb to infection within 4–5 days
Figure 4. Pathological changes in the spleens of SchuS4 infected mice following antibiotic therapy. Mice were infected intranasally with
50 CFU SchuS4. Three days after infection mice were treated once daily with 5 mg/kg LVF diluted in 5% dextrose water intraperitoneally for 14 days.
At the indicated time points, spleens from untreated, SchuS4 infected animals (C and D) and SchuS4 infected mice treated with LVF (E–P) were fixed,
sectioned, strained with H&E and assessed for pathological changes. Uninfected mice (A and B) served as normal controls. Representative
photomicrographs for each time point are shown. Plates A, C, E, G, I, K, M, and O are at 26magnification and plates B, D, F, H, J, L, N, P are 406
magnification of the areas indicated by the arrows on the 26plates.
doi:10.1371/journal.pone.0033349.g004
Figure 5. Bacterial loads and pathological changes in the lungs and spleens of SchuS4 infected mice following antibiotic therapy
that succumb to infection. Mice were infected intranasally with 50 CFU SchuS4. Three days after infection mice were treated once daily with
5 mg/kg LVF diluted in 5% dextrose water intraperitoneally for 14 days. After antibiotic treatment, mice (n=4) showing irreversible signs of illness
were euthanized. Lungs and spleens were collected and assessed for bacterial loads (A) or pathological changes (B–E). Representative
photomicrographs for each time point are shown. Plates B and D are at 26magnification and plates C and E are 406magnifications of the areas
indicated by the arrow on the corresponding 26plates.
doi:10.1371/journal.pone.0033349.g005
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mice that lack T cells bearing cdTCR survive primary SchuS4
infection (Figure 6B) and, of these survivors, 75% survive
secondary infection with SchuS4 (Figure 6B).
We next examined what contribution conventional B cells make
toward survival of SchuS4 infection. Similar to abTCR
2/2
animals, mice lacking mature, conventional B cells (mMT
2/2)d o
not succumb to infection during treatment with LVF, but die after
antibiotic therapy ended (Figure 6C). However, unlike mice
lacking abTCR, mMT
2/2 do not require euthanasia until 9–10
days (as opposed to 4–5 days in abTCR
2/2 mice) after ending
LVF treatment (Figure 6C).
Finally, using SCID mice we examined what effect absence of T
and B cells would have on the course of SchuS4 infection. As
observed in mice deficient for abTCR, cdTCR, and mMT, SCID
mice also survive infection during treatment with antibiotic.
However, SCID mice succumb to infection within 4 days after
administration of LVF ended (Figure 6D). Together these data
suggest that neither T cells nor B cells are required to control F.
tularensis infection during antibiotic therapy. However, both
abTCR
+ T cells and conventional B cells are required to survive
primary SchuS4 infection upon withdrawal of antibiotic. Finally,
compared to abTCR
+ cells, cdTCR
+ cells play a less pivotal role
in survival of primary and sequential secondary infection.
Sustained production of IL-12 in organs of SchuS4
infected mice
Our data suggests that both T cells (abTCR
+ and cdTCR
+) and
B cells are required to survive primary infection with virulent
SchuS4. Activation of T and B cells by cytokines can aid in
generation of optimal protective responses. T cells and B cells can
also secrete cytokines that contribute to killing microorganisms by
activating host cells to initiate anti-microbial defenses. Therefore,
we next assessed production and persistence of cytokines in the
lungs and spleens of SchuS4 infected animals treated with LVF
over time. At the indicated time points after infection, lung and
spleen homogenates were assessed for cytokines using multiplex
cytometric bead array and ELISA. IL-4, IL-5, and IL-17A were
not detected in any sample at concentrations that were
significantly different from uninfected controls at any time point
after infection (data not shown). In agreement with previous
reports, naı ¨ve, untreated, SchuS4 infected animals have signifi-
cantly higher concentrations of TNF-a, IL-6, IL-1b, MCP-
1(CCL2), and IL-10 in the lung and spleen on day 4 after
infection compared to uninfected controls (Figure 7, data not
shown and [47,48]). Four days after infection, animals treated with
LVF have similar concentrations of IL-6 and MIP-1a in their
lungs compared to untreated SchuS4 infected animals (Figure 7).
However, in contrast to untreated animals, spleens of mice treated
with LVF have significantly less TNF-a, IL-6, IFN-c, MCP-1, and
MIP-1a 4 days after infection (Figure 7). As the course of disease
progresses, IL-6, TNF-a, MCP-1, and MIP-1a are nearly
undetectable in the lungs and spleens by day 7 after infection
(Figure 7). In contrast, IL-12p40 was detected in these tissues at
concentrations that are significantly higher than those observed in
uninfected animals, even after 10 and 21 days of infection in the
spleen and lung, respectively (Figure 7). Together these data
suggest that extended SchuS4 infection correlates with cessation of
production of selected pro-inflammatory cytokines and chemo-
kines, e.g. TNF-a, IL-6, MCP-1 and MIP-1a and continued
production of IL-12p40 in target tissues.
IL-12 and IFN-c are required to survive F. tularensis
infection
IL-12 can act on T and NK cells to produce IFN-c [49] We and
others have shown that IFN-c can contribute to control of
intracellular replication of virulent and attenuated strains of F.
tularensis in vitro [50–52]. Furthermore, IFN-c is required for
survival of in vivo infection with attenuated strains of F. tularensis
[22,33]. The role of IL-12 in tularemia is unclear since one report
suggests neither IL-12p35 nor IL-12p40 are required to survive
infection with LVS, whereas others have shown both of these
Figure 6. Cellular requirements for survival of tularemia. abTCR
2/2 (n=5), cdTCR
2/2 (n=10), mMT
2/2 (n=5), SCID (n=10) and C57Bl/6 (n=5/
experiment) (wild type, WT) mice were intranasally infected with 50 CFU/25 ml SchuS4. Three days after infection mice were treated once daily with
5 mg/kg LVF diluted in 5% dextrose water intraperitoneally for 14 days. *=p,0.05 compared to untreated mice and LVF treated abTCR
2/2, cd TCR
2/2,
mMT
2/2, and SCID mice. Data in each graph is representative of 2 experiments of similar design.
doi:10.1371/journal.pone.0033349.g006
Host Requirements for Survival of Tularemia
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33349cytokines are essential [22,23]. In our model, IL-12p40 is detected for
up to 2 weeks in tissues of mice resolving SchuS4 infection (Figure 7).
Thus, we hypothesized that IL-12 may play an important role in
survival of infection with virulent F. tularensis. Similar to other
immunodeficient mice, all untreated IL-12p40
2/2 and IL-12p35
2/2
that were not treated with LVF succumb to SchuS4 infection within
4–5 days of inoculation (Figure 8). The mean time to death for both
groups of mice is not statistically different from untreated wild type
animals. In the presence of LVF, SchuS4 infected IL-12p40
2/2 and
IL-12p35
2/2 have significantly fewer survivors (10% and 0%,
respectively) compared to wild type animals (Figure 8A and 8B), but
do not succumb to disease until after LVF therapy ended. One IL-
12p40
2/2 animal remained after primary infection, thus we
determined if this animal could survive a second SchuS4 challenge.
The IL-12p40
2/2 animal died on day 9 after secondary infection
(data not shown). This suggests that IL-12p40 is also required to
survive secondary SchuS4 infection.
As described above, IL-12 is tightly associated with production
of IFN-c. IFN-c is well known for its role in protecting against
intracellular pathogens (as reviewed, [53,54]). Since IL-12 played a
critical part in survival of SchuS4 infection we hypothesized that
IFN-c may also be required to survive infection with this
bacterium. Interestingly, unlike all other genetically deficient mice
tested in this study, animals lacking IFN-cR fail to survive SchuS4
infection even in the presence of antibiotic (Figure 8C). Thus, IL-
12p40, IL-12p35, and IFN-c are required to survive primary
SchuS4 infection.
Both CD4
+ and CD8
+ cells contribute to IFN-c production
during SchuS4 infection
Data presented above indicates that both T cells and IFN-c are
required for survival of SchuS4 infection (Figure 6 and 8). Previous
reports have shown that following infection with attenuated
subspecies of F. tularensis, e.g. LVS, CD4
+ and NK cells are
primarily responsible for production of IFN-c in the lung and
spleen [55–58]. However, a similar analysis among naı ¨ve animals
infected with Type A F. tularensis has not been reported. Therefore,
we next determined which cell populations were responsible for
producing IFN-c during SchuS4 infection, if the cell type changed
over time, and if there were differences in IFN-c producing cells in
the lung and spleen. We first assessed changes in the overall cell
populations in the lung and spleen over time. In agreement with
pathology reported above, there is a general expansion in the
lymphocyte compartment in both the lung and spleen of SchuS4
infected animals within the first 7 days of infection (Figure 9A and
B). However, this expansion did not include NK cells which were
significantly reduced in both the lung and spleen at this time point
compared to uninfected controls at day 7 and 14 after infection
(Figure 9A and B). In the lung, there is evidence that the number
of CD8
+ cells are contracting by day 14 after infection and by day
21 CD4
+, CD8
+ and cdTCR
+ lymphocytes had all returned to
Figure 7. Cytokine production in target organs of SchuS4 infected mice following antibiotic therapy. C57Bl/6 mice were intranasally
with 50 CFU SchuS4. Three days after infection mice were treated once daily with 5 mg/kg LVF diluted in 5% dextrose water intraperitoneally for 14
days. At the indicated time points animals (n=5/group) were euthanized and lungs and spleens were homogenized. Homogenates were assessed for
presence of the indicated cytokines using Flex Set Cytometric Bead Array assay. Uninfected mice served as negative controls. *=p,0.01 compared to
uninfected mice. **=p,0.01 compared to uninfected and infected, untreated animals. ***=p,0.05 compared to all other groups. Error bars
represent SEM. Data is representative of 2 experiments of similar design.
doi:10.1371/journal.pone.0033349.g007
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the number of CD4
+, CD8
+ and cdTCR
+ cells returned to
numbers similar to uninfected controls (Figure 9B). The numbers
of CD4+ and CD8+ cells did not significantly change after this
time point. However, the number of splenic cdTCR
+ continued to
drop and was significantly lower at day 21 after infection
compared to uninfected controls (Figure 9B). We then determined
which populations of cells in the spleen and lung were producing
IFN-c. Within the first 7 days of infection we were able to detect
significantly higher numbers of CD4
+, CD8
+ and cdTCR
+ cell
populations that were positive for IFN-c in both the lung and
spleen compared to uninfected controls (Figure 9C). However,
more CD4
+ and CD8
+ are positive for IFN-c than cdTCR
+ cells
in both the lung and spleen at this time point after infection
(Figure 9). Additionally, although the overall numbers of
pulmonary NK cells decrease 7 days after infection (Figure 9A)
significantly more NK cells are positive for IFN-c compared to
uninfected controls at day 7 after infection (Figure 9C). In contrast,
NK cells do not appear to make a contribution toward production
of IFN-c in the spleen at any of the time points we tested
Figure 8. IL-12 and IFN-c are required to survive tularemia. IL-12p40
2/2 (n=10), IL-12p35
2/2 (n=10), IFN-cR
2/2 (n=10) and C57Bl/6 (n=5/
experiment) (wild type, WT) mice were intranasally infected with 50 CFU/25 ml SchuS4. Beginning on day 3 after infection, mice were treated once
daily with 5 mg/kg LVF diluted in 5% dextrose water for 14 days. *=p,0.05 compared to untreated mice and LVF treated IL-12p40
2/2, IL-12p35
2/2,
IFN-cR
2/2 animals. **=p,0.05 compared to all other groups of mice. Data in each graph is representative of 2 experiments of similar design.
doi:10.1371/journal.pone.0033349.g008
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+ and CD8
+ cells dominate the IFN-c
response in both the lung and spleen after SchuS4 infection, we
observed disparity in the contribution each of these cells made
toward production of IFN-c in each organ. For example, in the
lung, we observe similar, significantly higher numbers of IFN-
c
+CD4
+ and IFN-c
+CD8
+ cells at day 7 and 14 after infection
compared to uninfected controls (Figure 9C). However, by day 21
after infection there are no differences in the number of IFN-c
+
cells in the lung compared to uninfected mice (Figure 9C). In
contrast, at day 7 after infection we detect significantly more
CD8
+IFN-c
+ cells compared to all other cell types in the spleen
(Figure 9). As the infection progresses, first splenic CD4
+ cells are
the predominate IFN-c
+ cells (day 14) only to be usurped by CD8
+
cells at day 21 after infection (Figure 9D). We also assessed cellular
populations in animals euthanized at day 25 after infection and
found highly variable results with regard to both overall cell
numbers and populations of cells producing IFN-c. Specifically,
when bacterial loads are low we observe similar numbers of CD4
+
and CD8
+ cells in the lung and spleen. Moreover, both CD4
+ and
CD8
+ cells are positive for IFN-c in the lung and spleen with
slightly higher numbers of CD8
+IFN-c
+ cells in the spleen (Figure
S2). Animals that do not control bacterial replication had an
overall increase in CD4
+ and CD8
+ cells that was similar to the
response observed at day 7 after infection (Figure S2). The IFN-c
response in the lungs of these animals is dominated by CD4
+ cells
with only a modest contribution made by the CD8
+ cell
population (Figure S2). In the spleen, all cell types assessed are
positive for IFN-c among animals with high bacterial loads with
no clear preference toward cell type responding to infection
(Figure S2). Thus, at day 25 after infection there are some animals
that are clearly capable of controlling the recrudescence of SchuS4
growth following removal of antibiotic whereas other animals
cannot. However, the failure of some animals to control SchuS4
replication is not due to the inability of host cells to respond to
infection and produce IFN-c, but may lie in the proportion of the
cellular response or another undefined mechanism. Finally, our
data suggests that CD4
+ and CD8
+ cells make equal and transient
contributions toward production of IFN-c in the lung during the
first two weeks of infection, but are not sustained. In the spleen,
CD4
+ and CD8
+ cells vary in their contribution toward
production of IFN-c over the course of infection with CD8
+IFN-
c
+ cells persisting at later time points after infection.
Discussion
In the current report, we utilized antibiotic therapy to extend
the course of infection with virulent F. tularensis ssp. tularensis strain
SchuS4 in order to identify components of the immune response
that are required for survival of primary infection with SchuS4.
Using this approach, we successfully developed a model in which,
upon withdrawal of the antibiotic, the host response was ultimately
responsible for clearance of the pathogen. This feature was evident
in the uniform rise of bacterial numbers upon cessation of
antibiotic therapy in all animals. This was followed by complete
clearance of the bacterium and survival in 60% of the animals. We
then employed this in vivo model to identify host factors required
for survival of virulent F. tularensis infection. Consistent with
previous observations using mice with different immunodeficien-
cies than those examined here, we observe that untreated,
immunodeficient, mice infected with SchuS4 do not display rates
of survival or mean time to death that are significantly different
from untreated wild type animals (Figure 6 and 8, [40–42].
However, treatment with antibiotic extends mean time to death
and enhances survival of SchuS4 infected animals, thus allowing
better assessment of the role of specific host cells and molecules.
This model provides several novel findings which include a
requirement for conventional B cells, and to a lesser extent,
cdTCR
+ cells for survival of primary infection with virulent F.
tularensis. Further, our results clarify the role for IL-12p40 and IL-
12p35 following infection with F. tularensis by demonstrating that
both of these cytokines are required to survive primary SchuS4
infection. Finally, in agreement with previously published findings
using attenuated strains of F. tularensis, abTCR
+ cells and IFN-c
are required to survive infection ([32,33] and Figure 6 and 8).
Our most striking finding was the requirement for IFN-c.
Unlike all other knockout mice tested, mice deficient for IFN-c
receptor are unable to survive F. tularensis infection during
antibiotic therapy. It has been established that IFN-c is important
for resolution of a wide range of infections caused by intracellular
pathogens. For example, exogenous administration of recombi-
nant IFN-c contributes to the control of infection caused by Listeria
monocytogenes and Mycobacterium tuberculosis [59,60]. Alternatively,
neutralization of this cytokine increases bacterial loads and reduces
survival in mice infected with either of these bacteria [61,62]. IFN-
c has also been found to play a key role in control of infections
mediated by attenuated strains of F. tularensis [33,50,63]. The
mechanism of action for IFN-c is to activate professional antigen
presenting cells, such as macrophages, to kill phagocytosed
microorganisms. With respect to infection with F. tularensis,w e
and others have shown that one mechanism by which IFN-c
mediates killing of this intracellular pathogen is by activating
pathways that generate both reactive nitrogen species (RNS) and
reactive oxygen species (ROS) [51,52]. However, following in vitro
infection of macrophages with virulent F. tularensis, IFN-c must be
present either before cells are infected or within several hours after
infection to contribute to control of intracellular replication of F.
tularensis [51,52,64]. Similarly, results from our in vivo model
presented herein suggest that IFN-c must be present at early time
points after in vivo infection to ensure survival of tularemia.
Given the importance of IFN-c in survival of virulent F. tularensis
infection, identification of the cellular source of this cytokine, as
well as soluble mediators that contribute toward production of
IFN-c, is critical toward understanding the requirements of
protection against tularemia. IFN-c can be made by a variety of
cell types including, cdTCR
+, abTCR
+, and NK cells. In the
current manuscript, we provide direct evidence that abTCR
+ cells
and, to a smaller extent, cdTCR
+ cells are necessary to survive
primary SchuS4 infection (Figure 3). Thus, either of these cell
types may serve as a cellular source for IFN-c. However, since 0%
of mice lacking abTCR
+ cells survived primary SchuS4 infection
compared to survival of 30% of cdTCR
2/2 mice, our data
suggests that the role for abTCR
+ cells appears to be more critical
than the presence of cdTCR
+ cells. In agreement with this
hypothesis, higher numbers of CD4
+ and CD8
+ cells were positive
for IFN-c throughout SchuS4 infection in both the lung and
spleen compared to cdTCR
+ cells. This does not completely
preclude a role for cdTCR
+ cells in defense against F. tularensis. For
example, although cdTCR
+ cells are not required to survive
infection with attenuated F. tularensis, there is evidence that these
cells contribute to control of bacterial replication in the lung [65].
In that report, the proposed mechanism of action of cd T cells
against F. tularensis infection was secretion of IL-17A and not direct
secretion of IFN-c. IL-17A acts to support Th1 type immune
responses, induce production of anti-microbial peptides, and
enhance neutrophil expansion (as reviewed, [66]). We failed to
observe production of IL-17A in lung or spleen homogenates that
was significantly different from uninfected controls at any time
point after infection (data not shown). However, we did not
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sensitive method of detecting IL-17A may reveal a similar, small
role and function for cdTCR
+ cells during infection with virulent
F. tularensis as that observed with attenuated bacteria.
Among abTCR
+ cells, i.e. invariant NKT (iNKT) cells, CD4
+
T cells, and CD8
+ T cells, all can produce IFN-c [67–70]. The
role of iNKT cells in tularemia has not been defined. However,
iNKT cells have been shown to play a role in mediating protection
against other pulmonary pathogens following secretion of IFN-c
[71–73]. Thus, it is reasonable to speculate that these cells may
also contribute to control of virulent F. tularensis.
Presence of abTCR
+, CD4
+, and CD8
+ T cells have been
shown to be important for control of infection with attenuated F.
tularensis. Additionally, the presence of these cells have been show
to aid in mediating protective immunity against virulent F.
tularensis in vaccinated animals [32,34,46]. However, work
examining the cellular source of IFN-c following infection with
LVS has suggested that CD4
+ cells are the cell type primarily
responsible for producing this cytokine at later time points in
infection [55,56,58]. In the current study, our data suggests that
control of SchuS4 replication in the spleen following delivery of
levofloxacin is correlated with the presence of CD8
+ IFN-c
+ and
CD4
+ IFN-c
+ cells in this tissue. This result is consistent with our
previous observation in which expansion of IFN-c producing
CD4
+ and CD8
+ T cells in the spleens of LVS vaccinated animals
following infection with SchuS4 correlated with survival [74].
Together these data suggest that SchuS4 provokes a more complex
cellular response than that observed with attenuated subspecies of
F. tularensis. Understanding the relative contribution of both CD4
+
and CD8
+ T cell responses, rather than the primary CD4
+
response observed in LVS infected animals, is critical for
development of novel vaccines and the convalescent model
described herein might aid in that process. Identification of the
specific contribution of CD4
+ T cells, CD8
+ T cells and iNKT
cells toward control of F. tularensis infection is currently under
intense study in our laboratory.
In addition to determining the cellular source of IFN-c, it is also
important to identify the soluble mediators that contribute to
production of this cytokine. There are several cytokines that can
promote production of IFN-c from abTCR
+ cells including IL-
12p70 and IL-18. Among these, IL-12p70 represents one of the
most well studied cytokines. IL-12p70 is a heterodimer made up of
IL-12p40 and IL-12p35. IL-12p35 is constitutively expressed
whereas IL-12p40 requires activation of the cell prior to its
production. In addition to their function as IL-12p70, each of
these proteins can act independently or pair with other binding
partners to form cytokines with distinct functions. For example, in
the mouse IL-12p40 can be present as monomers or homodimers
that act as antagonists for IL-12p70 due to its high affinity for the
IL-12R [75]. IL-12p40 can also form heterodimers with p19 to
form IL-23. IL-23 has emerged as an important cytokine for the
production of IL-17 and the subsequent generation of Th17 type
immune responses dominated by inflammation and granulocytic
infiltrate [76].
Previously, it was shown that neither IL-12p35 nor IL-12p40
was required to survive infection with attenuated F. tularensis. This
suggested that IL-12p35 and, by extension, IL-12p70 was not
required for survival of attenuated F. tularensis infection. In
contrast, a more recent report showed that both IL-12p35 and
IL-12p40 were required for survival of LVS infection [23].
Figure 9. CD4
+ and CD8
+ cells are the primary producers of IFN-c during SchuS4 infection. Mice were intranasally infected with 50 CFU/
25 ml SchuS4. Beginning on day 3 after infection, mice were treated once daily with 5 mg/kg LVF diluted in 5% dextrose water for 14 days. At the
indicated time points lungs and spleens were assessed for the indicated cells and IFN-c by flow cytometry. *=p,0.05 compared to uninfected
controls. The color of the asterisk correlates with the same color of data points depicted on the graph.
doi:10.1371/journal.pone.0033349.g009
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have contributed to the dramatically different outcomes observed
by each lab, the fact remains that it is unclear what role, if any, IL-
12 played in infection with virulent F. tularensis. Results presented
herein agree with the more recent report in that both IL-12p35
and IL-12p40, and thus IL-12p70, are required for survival of
tularemia. However, since both IL-12p40 and IL-12p35 can act
independently of each other to mediate immune responses, it is
possible that the role of these proteins may be distinct from their
function in forming IL-12p70.
For example, it is possible that IL-12p35 may be working
independently to promote early inflammation, as recently
described in herpes stromal keratitis [77]. Alternatively, IL-
12p35 may partner with EBI3 to form IL-27. IL-27 is provoked
by a number of intracellular pathogens and has both pro- and anti-
inflammatory functions that contribute to control of infection (as
reviewed, [78]). The specific function of IL-12p35, IL-12p40, and
IL-12p70 in tularemia are currently under investigation in our
laboratory.
Finally, we determined that conventional B cells are required for
survival of SchuS4 infection (Figure 6). One function of B cells is
the production of antibody to aid in control of infection. Presence
of antibodies has been proposed to be important for protection
against tularemia. Indeed, passive transfer of immune serum and
monoclonal antibodies has successfully protected mice against
challenge with attenuated LVS [79–82]. In rats, passive transfer of
immune serum successfully protected against SchuS4 infection
[83]. Early studies in humans found that passive transfer of
hyperimmune serum generated in horses aided in control of active
cases of tularemia [38]. Thus, antibody can clearly support control
and clearance of F. tularensis. However, during infection of naı ¨ve
animals with virulent F. tularensis the requirement for antibody
versus other, unrelated activity exerted by B cells has not been
defined. B cells have additional functions outside of antibody
production that include production of cytokines such as IL-6,
antigen presentation, and regulation of dendritic cells (as reviewed,
[84]). Thus, B cells may serve in other ways to mediate protection
against F. tularensis infection that are unrelated to antibody
production. In support of this hypothesis, we previously demon-
strated that B cells, but not antibody, were critical for survival of
LVS infection in mice [44,45]. Importantly, recent preliminary
data generated in our laboratory using animals with specific
defects in their ability to produce and secrete antibody suggests
antibody is not required for survival of primary SchuS4 infection
(CM Bosio, unpublished observations). Thus, while antibody can
contribute to the clearance of F. tularensis, presence of this host
component may not be necessary to successfully resolve infection.
Rather, B cells may have other undefined functions to contribute
to survival of tularemia.
Over the past 10 years interest in disease caused by virulent F.
tularensis has increased, in part due to its potential as a biological
weapon [85]. Given the similarities of infectious dose required to
cause disease and the development of similar pathology between
human and mice exposed to virulent F. tularensis in the pulmonary
compartment, the mouse model of tularemia is a valuable tool for
the study of this disease in vivo. However, comprehensive
investigation of the cellular and soluble requirements for survival
of virulent F. tularensis infections were not possible due to the rapid
mean time to death following exposure of the animals to very low
doses of bacteria. Data presented herein demonstrates that low
dose antibiotic therapy can be used as a method to overcome this
hurdle. Thus, we can now gain a better understanding of
requirements for protection and survival of primary tularemia.
Furthermore, our model is also reminiscent of observations made
in humans following use of antibiotics for treatment of tularemia,
where both relapse and modest, but incomplete, protection against
re-infection have been noted [86–89]. Thus, our model will
provide a unique opportunity to study infection with virulent F.
tularensis that will reveal novel and unexpected functions for host
factors involved in both the resolution and exacerbation of
tularemia.
Materials and Methods
Ethics Statement
This study was carried out with strict accordance with the
recommendations made by the National Institutes of Health. The
protocol was approved by the animal care and use committee at
the Rocky Mountain Laboratories/NIAID/NIH, protocol num-
ber 2009-66.
Mice
Specific-pathogen-free, 6–8 week old C57Bl/6J (wild type),
B6.129S2-Tcra
tm1Mom/J (abTCR
2/2), B6.129P2-Tcrd
tm1Mom/J
(cdTCR
2/2), B6.129S2-Ighm
tm1Cgn/J (mMT
2/2), B6.CB17-
Prkdc
scid/SzJ (SCID), B6.129S1-Il12b
,tm1Jm./J (IL-12p35
2/2)
and B6.129S1-Il12a
tm1Jm/J (IL-12p40
2/2)(n=5–10/group) were
purchased from Jackson Laboratories (Bar Harbor, ME). Mice
lacking IFN-gamma receptor (IFN-cR
2/2) were bred at the
Rocky Mountain Laboratories (RML). Mice were housed in sterile
microisolater cages in the BSL-3 facility at the RML. All mice
were provided sterile water and food ad libitum and all research
involving animals was conducted in accordance with Animal Care
and Use guidelines and animal protocols were approved by the
Animal Care and Use Committee at RML. Following infection
mice were regularly monitored and euthanized at the first signs of
illness in accordance with Animal Care and Use guidelines and
animal protocols approved by the Animal Care and Use
Committee at RML.
Bacteria
Francisella tularensis ssp. tularensis strain SchuS4 was kindly
provided by Jeannine Peterson, Ph.D. (Centers for Disease
Control, Fort Collins, Colorado). SchuS4 was cultured in modified
Mueller-Hinton broth (Mueller-Hinton broth supplemented with
CaCl2, MgCl2, 0.1% glucose, 0.025% ferric pyrophosphate and
2% Medium Enrichment [50% glucose, 167 mM L-cysteine-HCl,
68 mM L-glutamine, mM adenine, 376 mM nicotinamide adenine
dinucleotide, 7 mM Vitamin B12, 217 mM thiamine pyrophos-
phate, 160 mM guanine-HCl, 50 mM ferric nitrate, 95 mM
aminobenzoic acid, 9 mM thiamine hydrocholride]) at 37uC with
constant shaking overnight, aliquoted into 1 ml samples, frozen at
280uC and thawed just prior to use as previously described [9].
Frozen stocks were titered by enumerating viable bacteria from
serial dilutions plated on modified Mueller-Hinton (MMH) agar as
previously described [33,44]. The number of viable bacteria in
frozen stock vials varied less than 1% over a 12 month period.
Infection of mice and administration of antibiotic
Mice were infected intranasally (i.n.) with approximately
50 CFU/25 ml F. tularensis SchuS4 as previously described [13].
Briefly, bacteria were thawed and diluted in PBS. Mice were
anesthetized by intraperitoneal injection of 100 ml of 12.5 mg/ml
ketamine+3.8 mg/ml xylazine. Approximately 50 CFU was
administered into the nares of each mouse in a total volume of
25 ml. Actual inoculum concentration was confirmed by plating a
portion of the inoculum onto MMH agar plates, incubating plates
at 37uC with 5%CO2 and enumerating colonies. At the indicated
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5 mg/kg levofloxacin (LVF) (Ortho-McNeil Pharmaceutical,
Raritan, NJ). Levofloxacin was prepared by diluting stock
antibiotic to the appropriate concentration in 5% dextrose water
immediately prior to use. Mice were injected intraperitoneally with
100 ml of diluted LVF once daily for 14 days. As indicated, mice
that survived primary SchuS4 challenge were given a second
intranasal infection of F. tularensis SchuS4 (50 CFU/25 ml) 30 days
after the initial infection. All mice were monitored for 30 days after
each infection. Following infection mice were monitored regularly
and euthanized at the first signs of illness. All experiments using
animals were performed in accordance with protocols approved by
the Animal Care and Use Committee at RML.
Collection of tissue homogenate and enumeration of
bacteria
Bacteria were enumerated from the lungs and spleens as
previously described [9,13]. Briefly, organs were aseptically
collected and placed in ice cold homogenization buffer (150 mM
Tris-HCl, 5 mM EDTA, 10 mM Trizma-base) supplemented with
a 1:100 dilution of Phosphatase Inhibitor cocktail I, Phosphatase
Inhibitor cocktail II and Protease Inhibitor cocktail III (all from
AG Scientific, San Diego, CA). Organs were immediately
homogenized by grinding tissues through a sterile S/S Type 304
#60 wire mesh screen (Billeville Wire Cloth Co., Cedar Grove,
New Jersey) using a 3 ml syringe plunger. A portion of the
resulting homogenate was immediately serially diluted in PBS and
plated on MMH agar for enumeration of bacterial loads. The
remaining homogenate was centrifuged at 14,0006g for 30 min at
4uC. The resulting supernatants were sterile filtered through
0.2 mm syringe filters (Millipore Ireland LTD, Cork, Ireland) and
stored at 280uC before assessment for cytokines.
Assessment of pathological changes in tissues
Tissues were fixed in 10% neutral buffered formalin for a
minimum of 24 hours. Tissues were embedded in paraffin, placed
in cassettes, and processed with a Sakura VIP-5 Tissue Tek, on a
12 hour automated schedule, using a graded series of ethanol,
xylene, and ParaPlast Extra. Embedded tissues are sectioned at
5 mm and dried overnight at 42uC prior to staining. Tissues
sections were stained with hematoxylin and eosin (H&E) and
examined on an Olympus BX51 light-microscope equipped with a
Olympus DP722 camera and associated cellSens Dimension 1.4.1
software. Tissues were assessed by a board certified pathologist.
Extent of necrosis, neutrophilia, lymphocyte depletion, extramed-
ullary hematopoiesis, and distribution of lesions was scored on a
scale of 0–5.
Isolation of lung and spleen cells
Lung cells and splenocytes were collected as previously
described with the following modifications [74]. Lung cells and
splenocytes were resuspended in FACS buffer prior to flow
cytometric analysis or DMEM supplemented with 10% heat-
inactivated fetal calf serum (FCS), 0.2 mM L-glutamine, 1 mM
HEPES buffer and 0.1 mM nonessential amino acids (all from
Invitrogen, Carlsbad, CA) (cDMEM) prior to addition to tissue
cultures. Total live cells from the lungs and spleens were
enumerated using trypan blue and a TC10 Automated Cell
Counter (Bio-Rad Laboratories, Hercules, CA).
Flow Cytometry
Lung and splenocyte populations were assessed by flow
cytometry as previously described [74]. Briefly, the following
antibodies in various combinations were used for flow cytometric
analysis: APC CD4, PerCPCy5.5 CD8, FITC NKp46, PeCy7
B220 and APC cdTCR (all from BD Biosciences, San Jose, CA).
Staining was performed in FACS buffer at room temperature.
Following staining, cells were washed and fixed in 1% parafor-
maldehyde for 30 minutes at 4uC. Cells were washed a final time,
resuspended in FACS buffer and stored at 4uC until analyzed.
Samples were collected using a LSRII flow cytometer (BD
Biosciences). Analysis gates were set on viable unstained cells
and were designed to include all viable cell populations.
Approximately 10,000 gated events were analyzed for each
sample. Isotype control antibodies were included when analyses
and panels were first being performed to assure specificity of
staining, but were not routinely included with each experiment.
Data was analyzed using FlowJo software (Treestar, Ashland, OR).
Intracellular cytokines were detected by flow cytometry as
previously described [14]. Single cell suspensions of lungs and
spleens were resuspended in cDMEM at 2610
5 per well in 96-well
plates in the presence of 10 mg/ml Brefeldin A, 10 ng/ml phorbol
12-myristate 13-acetate and 1 mg/ml ionomycin (all from Sigma)
at 37uC/5% CO2 for 4 hours. Following incubation, cells were
washed once and resuspended in FACS buffer and stained for
CD4, CD8, cdTCR and NKp46 as described above. Then cells
were fixed in 2% paraformaldehyde in PBS for 10 min at 37uC/
7% CO2 and washed twice more in ‘‘perm buffer’’ (FACS buffer
supplemented with 0.25% saponin [Sigma-Aldrich]). Cells were
incubated for 20 min at room temperature with anti-mouse IFN-c
(PE; clone XMG1.2) or PE conjugated rat IgG (isotype control)
(both from BDBiosciences). Cells were washed twice in perm
buffer, fixed in 1% paraformaldehyde for 30 min, and then
resuspended in FACS buffer and stored at 4uC until analysis. Cells
were acquired and analyzed using a LSR II flow cytometer (BD
Biosciences) and FlowJo Software (Treestar).
Measurement of cytokines
Organ homogenates were assayed for the presence of TNF-a,
IL-6, IL-10, IL-1b, IL-12p70, IL-17A, IL-5, IFN-c, MCP-1, and
MIP-1a, by Cytometric Bead Array using a LSRII multiparameter
flow cytometer and FCAP Array Software (all from BD
Biosciences) according to the manufacturer’s instructions. IL-4
and IL-12p40 was assessed by commercially available ELISA
according to manufacturer’s instructions (R&D Systems).
Detection of SchuS4 serum antibodies
Serum was collected from mice that survived SchuS4 infection
and LVF treatment 30 days after challenge. Presence of serum IgG
antibodies that recognize antigens in whole cell lysate prepared
from SchuS4 were detected as previously described [74].
Statistical Analysis
Statistical differences between two groups were determined
using an unpaired t test with the significance set at p,0.05. For
comparison between three or more groups, analysis was done by
one-way ANOVA followed by Tukey’s multiple comparisons test
with significance determined at p,0.05. Significance in survival
between groups was determined using Log-Rank (Mantel-Cox) test
with significance determined at p,0.05.
Supporting Information
Figure S1 Convalescent mice develop anti-SchuS4 anti-
bodies. Thirty days after challenge surviving mice were
euthanized and blood was collected via cardiac puncture. Serum
was isolated and tested for IgG antibodies directed against SchuS4
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control. Data is representative of 2 experiments of similar design.
(TIF)
Figure S2 Variable bacterial loads and cellular respons-
es in mice recovering from SchuS4 infection in the
absence of antibiotics. Mice were intranasally infected with
50 CFU/25 ml SchuS4. Beginning on day 3 after infection, mice
were treated once daily with 5 mg/kg LVF diluted in 5% dextrose
water for 14 days. Twenty-five days after infection lungs and
spleens were assessed bacterial loads (A) for the indicated cells and
IFN-c by flow cytometry (B and C). Bacterial loads and cellular
changes for individual mice are depicted on each graph.
(TIF)
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